Drug intelligence / Profile preview

ReOpt-NK

Development stage: Preclinical
Lead developer: Vycellix
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies

Overview

ReOpt-NK is a next-generation, retargeted and optimized natural killer (NK) cell-based cancer immunotherapy being developed by Vycellix, in collaboration with Karolinska Institutet. It is part of an early-stage pipeline of NK cell therapies aimed at treating hematological malignancies and solid tumors. The development is supported by the Competence Center for Next-Generation NK Cell-based Cancer Immunotherapy (NextGen-NK) at Karolinska Institutet.

Other names: Retargeted Optimized NK cell

Beyond the preview

Go deeper on ReOpt-NK.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReOpt-NK.

Explore the full profile